Artículos relacionados a Policy Issues in the Clinical Development and Use of...

Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer Treatment: Proceedings of a Workshop - Tapa blanda

National Academies Of Sciences, Engineering, And Medicine; Health And Medicine Division; Board On Health Care Services; National Cancer Policy Forum

 
9780309442329: Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer Treatment: Proceedings of a Workshop
Tapa blanda
ISBN 10: 030944232X ISBN 13: 9780309442329
Editorial: National Academies Press, 2016

Sinopsis

Immunotherapy is a form of cancer therapy that harnesses the bodya (TM)s immune system to destroy cancer cells. In recent years, immunotherapies have been developed for several cancers, including advanced melanoma, lung cancer, and kidney cancer. In some patients with metastatic cancers who have not responded well to other treatments, immunotherapy treatment has resulted in complete and durable responses. Given these promising findings, it is hoped that continued immunotherapy research and development will produce better cancer treatments that improve patient outcomes. With this promise, however, there is also recognition that the clinical and biological landscape for immunotherapies is novel and not yet well understood. For example, adverse events with immunotherapy treatment are quite different from those experienced with other types of cancer therapy. Similarly, immunotherapy dosing, therapeutic responses, and response time lines are also markedly different from other cancer therapies. To examine these challenges and explore strategies to overcome them, the National Academies of Sciences, Engineering, and Medicine held a workshop in February and March of 2016. This report summarizes the presentations and discussions from the workshop.

"Sinopsis" puede pertenecer a otra edición de este libro.

Reseña del editor

Immunotherapy is a form of cancer therapy that harnesses the bodya (TM)s immune system to destroy cancer cells. In recent years, immunotherapies have been developed for several cancers, including advanced melanoma, lung cancer, and kidney cancer. In some patients with metastatic cancers who have not responded well to other treatments, immunotherapy treatment has resulted in complete and durable responses. Given these promising findings, it is hoped that continued immunotherapy research and development will produce better cancer treatments that improve patient outcomes. With this promise, however, there is also recognition that the clinical and biological landscape for immunotherapies is novel and not yet well understood. For example, adverse events with immunotherapy treatment are quite different from those experienced with other types of cancer therapy. Similarly, immunotherapy dosing, therapeutic responses, and response time lines are also markedly different from other cancer therapies. To examine these challenges and explore strategies to overcome them, the National Academies of Sciences, Engineering, and Medicine held a workshop in February and March of 2016. This report summarizes the presentations and discussions from the workshop.

"Sobre este título" puede pertenecer a otra edición de este libro.

Editorial
National Academies Press
Año de publicación
2016
Idioma
Inglés
ISBN 10 
030944232X
ISBN 13 
9780309442329
Encuadernación
Tapa blanda
Número de edición
1
Número de páginas
134
Contacto del fabricante
no disponible
Persona responsable
no disponible